Regeneron Pharmaceuticals, Inc.
USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3 IN COMBINATION WITH 4-1BB CO-STIMULATION

Abstract:

Provided herein are methods of treating cancer using bispecific antigen-binding molecules that bind to prostate-specific membrane antigen (PSMA) and CD3. According to certain embodiments, the antibodies useful herein bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of prostate tumors expressing PSMA. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.